Parnell Pharmaceuticals Holdings (NASDAQ: PARN) and Mylan N.V. (NASDAQ:MYL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitabiliy, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Insider and Institutional Ownership

16.9% of Parnell Pharmaceuticals Holdings shares are owned by institutional investors. Comparatively, 69.9% of Mylan N.V. shares are owned by institutional investors. 0.7% of Mylan N.V. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Parnell Pharmaceuticals Holdings and Mylan N.V., as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Parnell Pharmaceuticals Holdings 0 0 0 0 N/A
Mylan N.V. 0 7 11 2 2.75

Mylan N.V. has a consensus target price of $50.83, suggesting a potential upside of 54.41%. Given Mylan N.V.’s higher possible upside, analysts clearly believe Mylan N.V. is more favorable than Parnell Pharmaceuticals Holdings.


This table compares Parnell Pharmaceuticals Holdings and Mylan N.V.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Parnell Pharmaceuticals Holdings -130.46% -83.86% -43.24%
Mylan N.V. 4.59% 23.69% 7.92%

Volatility and Risk

Parnell Pharmaceuticals Holdings has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Comparatively, Mylan N.V. has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Valuation & Earnings

This table compares Parnell Pharmaceuticals Holdings and Mylan N.V.’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Parnell Pharmaceuticals Holdings N/A N/A N/A N/A N/A
Mylan N.V. $11.61 billion 1.52 $3.80 billion $1.00 32.92

Mylan N.V. has higher revenue and earnings than Parnell Pharmaceuticals Holdings.


Mylan N.V. beats Parnell Pharmaceuticals Holdings on 10 of the 10 factors compared between the two stocks.

Parnell Pharmaceuticals Holdings Company Profile

Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Receive News & Ratings for Parnell Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parnell Pharmaceuticals Holdings Ltd and related companies with's FREE daily email newsletter.